Rifaximin Solid Dispersion Composition for Cirrhosis Complications
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical therapies for complications of cirrhosis, such as esophageal variceal bleeding, ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome, have poor survival rates, and there is a need for alternative formulations of rifaximin to improve patient outcomes.
Innovation Solution
A solid dispersion formulation of rifaximin comprising 16-18 wt% rifaximin, 16-18 wt% HPMC-AS, 1-2 wt% poloxamer 407, 8-10 wt% croscarmellose sodium, 49-51 wt% microcrystalline cellulose, 0.15-0.25 wt% colloidal silicon dioxide, and 0.45-0.55 wt% magnesium stearate, which is administered to reduce complications of liver disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional medical therapies are used for cirrhosis complications, then treatment is provided, but survival rates remain poor (20-50% five-year survival)
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical state of rifaximin through solid dispersion technology. The drug is transformed from its conventional crystalline form into an amorphous solid dispersion state within a polymer matrix (HPMC-AS), which fundamentally alters its dissolution characteristics and bioavailability parameters, enabling superior therapeutic effectiveness compared to conventional formulations
Solution Approach 2:
The patent employs composite materials by creating a solid dispersion system where rifaximin is intimately mixed with hydroxypropyl methylcellulose acetate succinate (HPMC-AS) polymer matrix. This composite structure combines the therapeutic agent with a biocompatible polymer carrier, producing a formulation that achieves enhanced drug release properties and improved clinical outcomes for cirrhosis complications
2Reliability
If rifaximin is formulated as solid dispersion with HPMC-AS, then therapeutic effectiveness is improved, but formulation complexity increases
Solution Approach 1:
The patent utilizes parameter changes by controlling the molecular weight range of HPMC-AS (100,000 to 1,000,000 Daltons) and optimizing the drug-polymer ratio to achieve the desired amorphous solid dispersion state. This parameter optimization enables effective drug delivery while managing formulation complexity through systematic control of critical quality attributes
Solution Approach 2:
The patent applies local quality by ensuring uniform distribution of rifaximin molecules within the HPMC-AS polymer matrix at the molecular level. This homogeneous local arrangement throughout the solid dispersion ensures consistent drug release behavior and therapeutic effectiveness, while the amorphous structure simplifies the overall formulation architecture compared to complex multi-component systems
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.